Xintela AB (publ)

0,29

Kursmål

Det gennemsnitlige kursmål for Xintela AB (publ) aktien er ikke tilgængeligt, det kan betyde, at der ikke er sat et kursmål for aktien, da den er meget lille eller helt ny og derfor ikke dækkes af større banker endnu, vi vil selvfølgelig opdatere dette kursmål, når det kommer.

Om Xintela AB (publ) aktien

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden. Læs mere
Kr. 156M Markedsværdi (Mcap)
Kr. 377K Omsætning
Bioteknologi Industri
Sverige Handles på børsen
xintela.se Hjemmeside
Sundhed Sektor